Sage Therapeutics reported positive topline data from the pivotal WATERFALL Study of zuranolone in patients with MDD, showing a statistically significant and clinically meaningful reduction in depressive symptoms. The company is advancing its pipeline, including the initiation of Phase 1 program for SAGE-689 and first patient dosed in SAGE-718 PARADIGM Parkinson’s disease Study Part B. Net revenue from sales of ZULRESSO was $1.6 million.
WATERFALL Study of zuranolone in MDD patients met primary endpoint with statistically significant reduction in depressive symptoms.
Pipeline expansion continued with advancement of brain health franchises and initiation of Phase 1 program for SAGE-689.
First patient dosed in SAGE-718 PARADIGM Parkinson’s disease Study Part B.
Updated enrollment guidance for Phase 3 SKYLARK Study of zuranolone in PPD, with topline data expected mid-2022.
Sage anticipates having cash, cash equivalents, and marketable securities of more than $1.7 billion at the end of 2021 and does not anticipate receipt of any milestone payments from collaborations in 2021.
Analyze how earnings announcements historically affect stock price performance